A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)

Inclusion Criteria: * Informed consent from participant * Age ≥18 years and \<50 years * Primary PPH defined as bleeding from uterus and/or the birth canal within 24 hours postpartum * Vaginal delivery or Cesarean delivery (irrespective of etiology of PPH, such as accreta), with EBL \>1000 mL and ongoing bleeding notwithstanding standard treatment measures (volume replacement, uterine massage, uterotonic agents) * FIBTEM®- A10 \<18 mm (corresponding to a MCF value of \<20 mm and to a plasma fibrinogen level approximately \<3 g/L) Exclusion Criteria: * Refusal to give written informed consent * Refusal to receive blood transfusion * Known inherited deficiencies of coagulation * Personal history of thrombosis * Either pre-pregnancy or ante-partum antithrombotic treatment due to increased risk of thrombosis * Administration of Platelets, FFP or cryotherapy prior to study drug